Lorazepam
Generic name: lorazepam · Brand names: Ativan, Lorazepam Intensol, Loreev XR
Quick facts
Drug class
Source
openFDA openfda.pharm_class_epc for generic_name lorazepam (api.fda.gov, fetched 2026-11-02)
Source text (exact source wording)
Benzodiazepine [EPC]
Rx or otc
Rx (DailyMed Product Type: HUMAN PRESCRIPTION DRUG)
Controlled schedule
Schedule IV (label: 'Lorazepam tablets contain lorazepam, a Schedule IV controlled substance.'; DailyMed DEA Schedule CIV)
Forms and strengths
- Tablet 0.5 mg, white to off-white, round, biconvex, debossed 'E' on one side and '1' on the other side
- Tablet 1 mg, scored, debossed 'E' above the score on one side and '2' on the other side
- Tablet 2 mg, scored, debossed 'E' above the score on one side and '3' on the other side
Generic available
Value
yes
Source
DailyMed: ANI label is marketing category ANDA (ANDA077396); other ANDA labels seen: Aurolife ANDA203572, Rising ANDA218597, Teva ANDA072926
Common use one line
Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. (Indications & Usage)
What it is used for
Lorazepam is used to manage anxiety disorders or to give short-term relief of anxiety symptoms, including anxiety that comes with depressive symptoms. Everyday stress usually does not need this kind of medicine. It has not been studied in long-term use of more than 4 months, so the prescriber should check regularly that it is still useful.
Section
INDICATIONS & USAGE
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.
How it works
Lorazepam is a benzodiazepine. MedlinePlus says it works by slowing activity in the brain to allow for relaxation. The label does not give a detailed mechanism.
Section
Clinical Pharmacology; MedlinePlus
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3); MedlinePlus lorazepam page (Last Revised - 11/15/2025)
Medlineplus source text (exact source wording)
Lorazepam is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow for relaxation.
Dosage: adults
The label says the dose should be matched to each person. The usual range is 2 to 6 mg/day in divided doses, with the largest dose before bedtime, but it may vary from 1 to 10 mg/day. For anxiety, most people start at 2 to 3 mg/day, taken two times a day or three times a day. For insomnia due to anxiety or short-term stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. Doses are raised gradually, and the evening dose is raised first. Stopping or lowering the dose should be done with a gradual taper.
Section
DOSAGE AND ADMINISTRATION
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy should be individualized according to patient response. To facilitate this, 0.5 mg, 1 mg, and 2 mg tablets are available.
The usual range is 2 to 6 mg/day given in divided doses, the largest dose being taken before bedtime, but the daily dosage may vary from 1 to 10 mg/day.
For anxiety, most patients require an initial dose of 2 to 3 mg/day given two times a day or three times a day.
For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime.
The dosage of lorazepam tablets should be increased gradually when needed to help avoid adverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses.
Discontinuation or Dosage Reduction of Lorazepam Tablets
To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly (see WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence).
The usual range is 2 to 6 mg/day given in divided doses, the largest dose being taken before bedtime, but the daily dosage may vary from 1 to 10 mg/day.
For anxiety, most patients require an initial dose of 2 to 3 mg/day given two times a day or three times a day.
For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime.
The dosage of lorazepam tablets should be increased gradually when needed to help avoid adverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses.
Discontinuation or Dosage Reduction of Lorazepam Tablets
To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly (see WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence).
Dosage: children
The label says safety and effectiveness have not been established in children less than 12 years of age. No pediatric dosing is given in the label. Paradoxical reactions may be more likely in children and the elderly (see Warnings).
Section
PRECAUTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Safety and effectiveness of lorazepam in children of less than 12 years have not been established.
Dosage adjustments
Drug interaction caps
Items
With valproate, the label says lorazepam dosage should be reduced to approximately 50%.
Section
PRECAUTIONS: Drug Interactions
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately 50% when co-administered with valproate.
With probenecid, the label says lorazepam dosage needs to be reduced by approximately 50%.
Section
PRECAUTIONS: Drug Interactions
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Concurrent administration of lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately 50% when coadministered with probenecid.
Kidney
The label says to use the usual precautions in people with kidney or liver problems. No specific kidney dose is given.
Section
PRECAUTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
The usual precautions for treating patients with impaired renal or hepatic function should be observed.
Liver
Lorazepam can worsen hepatic encephalopathy, so it should be used with caution in severe liver problems. Dose is adjusted carefully, and lower doses may be enough.
Section
PRECAUTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
As with all benzodiazepines, the use of lorazepam may worsen hepatic encephalopathy; therefore, lorazepam should be used with caution in patients with severe hepatic insufficiency and/or encephalopathy. Dosage for patients with severe hepatic insufficiency should be adjusted carefully according to patient response; lower doses may be sufficient in such patients.
Elderly
For older or weakened people, the label recommends an initial dosage of 1 to 2 mg/day in divided doses, adjusted as needed and tolerated. The initial dosage should not exceed 2 mg. These patients may be more sensitive to sedation and should be monitored often.
Section
DOSAGE AND ADMINISTRATION; PRECAUTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended, to be adjusted as needed and tolerated.
(PRECAUTIONS) Elderly or debilitated patients may be more susceptible to the sedative effects of lorazepam. Therefore, these patients should be monitored frequently and have their dosage adjusted carefully according to patient response; the initial dosage should not exceed 2 mg.
(PRECAUTIONS) Elderly or debilitated patients may be more susceptible to the sedative effects of lorazepam. Therefore, these patients should be monitored frequently and have their dosage adjusted carefully according to patient response; the initial dosage should not exceed 2 mg.
Missed dose
MedlinePlus says to skip the missed dose and continue your regular schedule. Do not take a double dose to make up for a missed one.
Section
What should I do if I forget a dose?
Source
MedlinePlus lorazepam page (Last Revised - 11/15/2025)
Medlineplus source text (exact source wording)
If you miss a dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Overdose
Overdose causes central nervous system depression, from drowsiness to coma. Mild to moderate cases can include drowsiness, confusion, lethargy, and poor coordination. Severe cases can lead to slowed breathing and coma. Overdose with other CNS depressants such as alcohol and opioids may be fatal. Call Poison Help at 1-800-222-1222. MedlinePlus also says to call emergency services at 911 if the person has collapsed, had a seizure, has trouble breathing, or can't be awakened.
Section
OVERDOSAGE; MedlinePlus In case of emergency/overdose
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Overdosage of benzodiazepines is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness) may occur. In severe overdosage cases, patients may develop respiratory depression and coma. Overdosage of benzodiazepines in combination with other CNS depressants (including alcohol and opioids) may be fatal (see WARNINGS: Abuse, Misuse, and Addiction). Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
[MedlinePlus] If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
[MedlinePlus] If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Storage
Store at 20°C to 25°C (68°F to 77°F). Keep the bottle tightly closed and out of reach of children.
Section
HOW SUPPLIED (ANI-specific; other labelers may differ)
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Keep bottles tightly closed.
Keep out of reach of children.
Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
Dispense in a tight container.
Keep out of reach of children.
Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
Dispense in a tight container.
Boxed warning
Using lorazepam with opioids can cause profound sedation, slowed breathing, coma, and death. Lorazepam can be abused, misused, and become addictive, which can lead to overdose or death. Taking it for a long time can cause physical dependence, and stopping suddenly can cause withdrawal reactions that can be life-threatening, so it should be tapered gradually.
Section
BOXED WARNING
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS).
The use of benzodiazepines, including lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing lorazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS).
The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage (DOSAGE AND ADMINISTRATION and WARNINGS).
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS).
The use of benzodiazepines, including lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing lorazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS).
The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage (DOSAGE AND ADMINISTRATION and WARNINGS).
Contraindications
Do not use lorazepam if you are allergic to benzodiazepines or any part of the tablet, or if you have acute narrow-angle glaucoma.
Section
CONTRAINDICATIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Lorazepam is contraindicated in patients with:
• hypersensitivity to benzodiazepines or to any components of the formulation
• acute narrow-angle glaucoma.
• hypersensitivity to benzodiazepines or to any components of the formulation
• acute narrow-angle glaucoma.
Warnings and precautions
Using lorazepam with opioids can cause profound sedation, slowed breathing, coma, and death. It is reserved for people with no adequate alternatives.
Heading
Risks from Concomitant Use with Opioids
Section
WARNINGS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Concomitant use of benzodiazepines, including lorazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.
Lorazepam can be abused, misused, and become addictive, which can lead to overdose or death. Using other medicines, alcohol, or street drugs with it raises the chance of serious problems.
Heading
Abuse, Misuse, and Addiction
Section
WARNINGS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
The use of benzodiazepines, including lorazepam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see DRUG ABUSE AND DEPENDENCE: Abuse).
Taking lorazepam for a long time can cause physical dependence. Stopping suddenly or lowering the dose too fast can cause withdrawal reactions, including seizures, that can be life-threatening.
Heading
Dependence and Withdrawal Reactions
Section
WARNINGS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) (see DRUG ABUSE AND DEPENDENCE: Dependence).
Some people have withdrawal symptoms that last weeks to more than 12 months.
Heading
Protracted Withdrawal Syndrome
Section
WARNINGS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months (see DRUG ABUSE AND DEPENDENCE: Dependence).
Depression can appear or get worse during use. Lorazepam is not recommended for primary depressive disorder or psychosis.
Heading
Depression and psychosis
Section
WARNINGS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Pre-existing depression may emerge or worsen during use of benzodiazepines including lorazepam. Lorazepam is not recommended for use in patients with a primary depressive disorder or psychosis.
Lorazepam can cause potentially fatal slowed breathing, alone or with other CNS depressants. Do not operate dangerous machinery or motor vehicles, and expect less tolerance for alcohol.
Heading
Respiratory depression and driving
Section
WARNINGS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Use of benzodiazepines, including lorazepam, both used alone and in combination with other CNS depressants, may lead to potentially fatal respiratory depression (see PRECAUTIONS: Drug Interactions). As with all patients on CNS-depressant drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other CNS depressants will be diminished.
Use late in pregnancy can cause sedation or withdrawal symptoms in the newborn.
Heading
Neonatal Sedation and Withdrawal Syndrome
Section
WARNINGS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Use of lorazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate (see PRECAUTIONS: Pregnancy).
Use with caution in people with breathing problems such as COPD or sleep apnea syndrome.
Heading
Compromised respiratory function
Section
PRECAUTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Lorazepam should be used with caution in patients with compromised respiratory function (e.g., COPD, sleep apnea syndrome).
In people with depression, suicide is a possibility and benzodiazepines should not be used without adequate antidepressant therapy.
Heading
Suicide risk in depression
Section
PRECAUTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
In patients with depression, a possibility for suicide should be borne in mind; benzodiazepines should not be used in such patients without adequate antidepressant therapy.
Unexpected reactions have occasionally been reported, and may be more likely in children and older adults. If they happen, the drug should be stopped.
Heading
Paradoxical reactions
Section
PRECAUTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Paradoxical reactions have been occasionally reported during benzodiazepine use. Such reactions may be more likely to occur in children and the elderly. Should these occur, use of the drug should be discontinued.
Periodic blood counts and liver function tests are recommended for long-term therapy.
Heading
Essential Laboratory Tests
Section
PRECAUTIONS: Information for Patients
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Some patients on lorazepam have developed leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are recommended for patients on long-term therapy.
Pregnancy and breastfeeding
Babies born to mothers who used benzodiazepines late in pregnancy have been reported to have sedation or withdrawal symptoms. Published studies do not report a clear link to major birth defects. Lorazepam is present in breast milk, and infants have had sedation, poor feeding and poor weight gain, so they should be monitored. Tell your provider if you are pregnant or breastfeeding.
Section
PRECAUTIONS: Pregnancy; Nursing Mothers (ellipsis marks omitted text within the Risk Summary)
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal (see WARNINGS: Neonatal Sedation and Withdrawal Syndrome and Clinical Considerations). Available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see Data).
Nursing Mothers - Risk Summary: Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. ... Infants exposed to lorazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain.
Nursing Mothers - Risk Summary: Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. ... Infants exposed to lorazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain.
Side effects
Common
In about 3500 patients treated for anxiety, the most frequent adverse reaction was sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). Sedation and unsteadiness were more common with age.
Threshold
The label gives no percentage cut-off. It states: 'In a sample of about 3500 patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%).'
Section
ADVERSE REACTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
In a sample of about 3500 patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). The incidence of sedation and unsteadiness increased with age.
Less common
The label lists many other reactions without percentages, including fatigue, drowsiness, memory problems, confusion, and nausea. No placebo-controlled percentages are given.
Section
ADVERSE REACTIONS
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Serious
Label
Serious problems named in the label include potentially fatal slowed breathing, life-threatening withdrawal reactions such as seizures, and paradoxical reactions such as aggression and hallucinations.
Source
ANI label (set ID 787240e9-67b5-4af3-b16d-7cf314e3f2e3)
Source text (exact source wording)
Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. (ADVERSE REACTIONS) ... Use of benzodiazepines, including lorazepam, both used alone and in combination with other CNS depressants, may lead to potentially fatal respiratory depression (WARNINGS) ... Acute withdrawal reactions, which can be life-threatening (e.g., seizures) (WARNINGS).
Medlineplus
MedlinePlus says to call your doctor immediately or get emergency care for rash, hives, itching, swelling of the face, eyes, or mouth, wheezing, shortness of breath, or yellowing of skin or eyes.
Source
MedlinePlus lorazepam page (Last Revised - 11/15/2025)
Source text (exact source wording)
Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNINGS section, call your doctor immediately or get emergency medical treatment: rash; hives; itching; swelling of the face, eyes, or mouth; wheezing; or shortness of breath; yellowing of skin or eyes
Interactions
Drugs
Using lorazepam with opioids raises the risk of slowed breathing. Dose and duration should be limited and patients monitored closely.
Name
Opioids
Section
PRECAUTIONS: Drug Interactions
Source text (exact source wording)
The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation.
Lorazepam adds to the CNS-depressant effects of alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics.
Name
Other CNS depressants
Section
PRECAUTIONS: Drug Interactions
Source text (exact source wording)
The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics.
With clozapine, lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest.
Name
Clozapine
Section
PRECAUTIONS: Drug Interactions
Source text (exact source wording)
Concomitant use of clozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest.
Valproate raises lorazepam levels. The label says to reduce the lorazepam dosage to approximately 50%.
Name
Valproate
Section
PRECAUTIONS: Drug Interactions
Source text (exact source wording)
Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately 50% when co-administered with valproate.
Probenecid can make lorazepam act faster or longer. The label says to reduce the lorazepam dosage by approximately 50%.
Name
Probenecid
Section
PRECAUTIONS: Drug Interactions
Source text (exact source wording)
Concurrent administration of lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately 50% when coadministered with probenecid.
Theophylline or aminophylline may reduce the sedative effects of lorazepam.
Name
Theophylline or aminophylline
Section
PRECAUTIONS: Drug Interactions
Source text (exact source wording)
Administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam.
Food and alcohol
Tolerance for alcohol will be diminished while taking lorazepam. MedlinePlus says to talk to your doctor about safe use of alcohol and that alcohol can make side effects worse.
Name
Alcohol
Section
WARNINGS
Source text (exact source wording)
As with all patients on CNS-depressant drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other CNS depressants will be diminished.
Name
Food (MedlinePlus)
Section
MedlinePlus: What special dietary instructions should I follow?
Source text (exact source wording)
Unless your doctor tells you otherwise, continue your normal diet. (MedlinePlus: tablets and concentrate are taken with or without food.)
Other
Flumazenil can trigger withdrawal reactions, including seizures, in people dependent on lorazepam.
Name
Flumazenil
Section
WARNINGS
Source text (exact source wording)
Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures)
Patient tips
Label medication guide
Take it exactly as prescribed, do not share it, and do not stop suddenly. Do not drive or do dangerous activities until you know how it affects you. Do not drink alcohol or use other sleepy-making drugs without talking to your provider. Get emergency help for shallow or slowed breathing, breathing that stops, or excessive sleepiness.
Source
ANI Medication Guide (Revised: 11/2024)
Source text (exact source wording)
Do not suddenly stop taking lorazepam tablets. ... Take lorazepam tablets exactly as your healthcare provider prescribed. Do not share your lorazepam tablets with other people. Keep lorazepam tablets in a safe place and away from children. ... Do not drive, operate heavy machinery, or do other dangerous activities until you know how lorazepam tablets affect you. Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking lorazepam tablets without first talking to your healthcare provider. ... Get emergency help right away if any of the following happens: shallow or slowed breathing; breathing stops (which may lead to the heart stopping); excessive sleepiness (sedation)
Medlineplus
Do not stop or skip doses without talking to your doctor, who will probably lower the dose gradually. Do not take more, more often, or for longer than directed. It may make you drowsy, so do not drive or operate machinery until you know how it affects you.
Source
MedlinePlus lorazepam page (Last Revised - 11/15/2025)
Source text (exact source wording)
Do not stop taking this medication or take fewer doses without talking to your doctor. Your doctor probably will decrease your lorazepam dose gradually. ... Do not take a larger dose, take it more often, or for a longer time than your doctor tells you to. ... you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.
Alternatives
Class
Benzodiazepine [EPC]
Class source
openFDA openfda.pharm_class_epc for lorazepam (fetched 2026-11-02)
Indication source
ANI label Indications & Usage (anxiety disorders)
Note
No recommendation made.
Frequently asked questions
Question
What is lorazepam used for?
Answer
Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. MedlinePlus also says it is used to relieve anxiety and treat insomnia.
Source section
INDICATIONS & USAGE; MedlinePlus
Source
ANI label; MedlinePlus
Question
Can I take lorazepam with food?
Answer
MedlinePlus says the tablets are taken with or without food, two or three times a day, and to take it at bedtime if used for insomnia. Continue your normal diet unless your doctor says otherwise.
Source section
How should this medicine be used?
Source
MedlinePlus
Question
What should I do if I miss a dose?
Answer
MedlinePlus says to skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Source section
What should I do if I forget a dose?
Source
MedlinePlus
Question
Can I drink alcohol with lorazepam?
Answer
Tolerance for alcohol will be diminished, and alcohol and other CNS depressants add to the CNS-depressant effects. The Medication Guide says not to drink alcohol or take other drugs that may make you sleepy or dizzy without first talking to your healthcare provider.
Source section
WARNINGS; Medication Guide
Source
ANI label
Question
What are the most common side effects?
Answer
In a sample of about 3500 patients treated for anxiety, the most frequent adverse reaction was sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%).
Source section
ADVERSE REACTIONS
Source
ANI label
Question
Is lorazepam safe during pregnancy or breastfeeding?
Answer
Use late in pregnancy can result in sedation and/or withdrawal symptoms in the newborn. Lorazepam is present in breast milk, and infants should be monitored for sedation, poor feeding and poor weight gain. Tell your provider if you are pregnant or breastfeeding.
Source section
WARNINGS; PRECAUTIONS: Pregnancy, Nursing Mothers
Source
ANI label
Question
What should I not combine with lorazepam?
Answer
Opioids can cause profound sedation, respiratory depression, coma, and death. Other CNS depressants add to the effects. The label also names clozapine, valproate, probenecid, and theophylline or aminophylline.
Source section
BOXED WARNING; PRECAUTIONS: Drug Interactions
Source
ANI label
Question
Can I stop lorazepam when I feel better?
Answer
Do not suddenly stop taking lorazepam tablets. Stopping suddenly can cause serious and life-threatening side effects. The label says to use a gradual taper to discontinue or reduce the dosage.
Source section
Medication Guide; DOSAGE AND ADMINISTRATION
Source
ANI label
Sources
- DailyMed ANI Pharmaceuticals lorazepam tablets (PRIMARY)
Set id: 787240e9-67b5-4af3-b16d-7cf314e3f2e3 · Label effective or revised date: Revised: 7/2026 (end of label); Medication Guide and How Supplied: Revised 11/2024 / Rev 11/24 · Dailymed version date: 2026-07-16 (DailyMed publish date) · Fetched at: 2026-11-02 · Sections used: Boxed Warning, Description, Clinical Pharmacology, Indications, Contraindications, Warnings, Precautions, Adverse Reactions, Drug Abuse and Dependence, Overdosage, Dosage and Administration, How Supplied, Medication Guide - DailyMed alternate: Aurolife Pharma lorazepam tablets
Set id: 5b851f67-309d-4ef3-8b4b-ade8908256ea · Label effective or revised date: Revised: 12/2025 (also 06/2023 in body) · Dailymed version date: 2025-12-16 · Fetched at: 2026-11-02 · Sections used: revised date and marketing category only - DailyMed alternate: Rising Pharma lorazepam tablets
Set id: 386255e2-65aa-48ce-9eb1-246f1493cc14 · Label effective or revised date: Revised: 7/2025 · Dailymed version date: 2025-08-01 · Fetched at: 2026-11-02 · Sections used: revised date only - DailyMed Teva lorazepam tablets (opened, not chosen)
Set id: 1bf22e97-9425-484d-bac6-519c6bae6a37 · Label effective or revised date: Revised: 6/2023 · Dailymed version date: 2024-11-04 · Fetched at: 2026-11-02 · Sections used: revised date only - DailyMed Ativan brand label (Bausch Health)
Set id: 89057c93-8155-4040-acec-64e877bd2b4c · Label effective or revised date: Revised: 07/2025 · Dailymed version date: 2025-11-26 · Fetched at: 2026-11-02 · Sections used: revised date, marketing category, partial comparison - MedlinePlus Lorazepam
Label effective or revised date: Last Revised - 11/15/2025 · Fetched at: 2026-11-02 · Sections used: all - openFDA drug label API
Fetched at: 2026-11-02 · Sections used: openfda.pharm_class_epc - Drugs@FDA
Fetched at: 2026-11-02 · Sections used: NOT FOUND (not searched in this run) - Liverpool HIV/HEP checkers
Sections used: not applicable: the label's interaction section lists no antiviral drugs
Information is taken from the cited sources and is for general reference only. It is not medical advice. Report side effects to FDA MedWatch at 1-800-FDA-1088. For a poison emergency call 1-800-222-1222. See prices for this drug